Comparable stake leader
T. Rowe Price Investment Management, Inc.
SEC ownership of Immunome Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001472012.
Disclosed value leader
T. Rowe Price Investment Management, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- IMNM on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
T. Rowe Price Investment Management, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
T. Rowe Price Investment Management, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001472012
- Issuer location
- Bothell, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Immunome Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
T. Rowe Price Investment ...
Disclosed value leader
T. Rowe Price Investment ...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 17%
13D/G row: T. Rowe Price Investment Management, Inc.
Showing 1-8 of 50 holder rows.
Quick read
T. Rowe Price Investment Management, Inc. leads the comparable SEC ownership view at 17%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens T. Rowe Price Investment Management, Inc.'s linked filing trail.
Comparable ownership
Top 5
T. Rowe Price Investment Manageme...
17%
FMR LLC
15%
Immunome Aggregator, LP
6%
Redmile Group, LLC
4.9%
EcoR1 Capital, LLC
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
17%
|
$472,441,961
19,676,883 shares
|
+$79,542,057 | 30 Jun 2026 |
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$359,966,248
16,987,553 shares
|
— | 30 Jun 2026 |
| Immunome Aggregator, LP |
13D/G
|
6%
|
$40,628,327
4,768,583 shares
|
$0 | 31 Jan 2025 |
| Redmile Group, LLC |
13D/G
13F
Company
|
4.9%
|
$119,960,738
5,558,885 shares
|
-$3,442,010 | 31 Mar 2026 |
| EcoR1 Capital, LLC |
13D/G
|
4.7%
|
$34,756,616
4,079,415 shares
|
$0 | 31 Mar 2025 |
| Sirenia Capital Management LP |
13D/G
|
4.3%
|
$116,023,019
4,832,279 shares
|
-$49,525,931 | 30 Jun 2026 |
| Enavate Sciences GP, LLC |
13F
13D/G
Company
|
4.3%
from 13D/G
|
$76,576,401
3,613,799 shares
|
— | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
2.2%
|
$16,313,738
1,914,758 shares
|
-$13,130,862 | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$24,868,247.
Buys
$2,305,990
Insiders: 3
Sells
$27,174,237
Insiders: 7
Net
-$24,868,247
Shares: -1,103,980
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 111,468
Shares: 1,215,448
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 10,500 | 692,810 | $204,260 | $15,879,377 | -$15,675,117 |
| 3-6 | 32,450 | 139,438 | $647,772 | $2,964,780 | -$2,317,009 |
| 6-9 | 68,518 | 383,200 | $1,453,958 | $8,330,080 | -$6,876,121 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 26 reporting-owner rows connected to Immunome Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
26
Largest Forms 3/4/5 holder
Clay B. Siegall
Net 12M change
-$24,868,246
Latest report
10 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Clay B. Siegall | President and CEO, Director | $18,450,217 | +$1,749,660 | +10% | Median | 23 Jul 2026 |
| Michael Rapp | Director | $7,564,292 | Mixed | 02 Oct 2023 | ||
| Philip Wagenheim | Director | $7,044,685 | -$1,335,626 | -16% | Filing P/S | 10 Jun 2026 |
| Isaac Barchas | Director | $2,512,749 | -$18,274,988 | -88% | Filing P/S | 10 Aug 2026 |
| Max Rosett | Chief Financial Officer | $2,146,271 | -$2,518,716 | -54% | Median | 23 Jul 2026 |
| Philip Tsai | Chief Technical Officer | $1,728,044 | +$204,900 | +13% | Median | 23 Jul 2026 |
| Robert Lechleider | Chief Medical Officer | $1,479,167 | -$2,335,993 | -61% | Median | 23 Jul 2026 |
| Jack Higgins | Chief Scientific Officer | $1,340,267 | -$204,238 | -13% | Median | 23 Jul 2026 |
| Sandra G. Stoneman | Chief Legal Officer & Gc | $928,227 | Median | 23 Jul 2026 | ||
| Jean Jacques Bienaime | Director | $836,607 | +$147,610 | +21% | Filing P/S | 10 Jun 2026 |
| Franklyn G. Prendergast | Director | $359,564 | Mixed | 02 Oct 2023 | ||
| Bruce Turner | Chief Strategy Officer | $249,993 | Filing P/S | 09 Aug 2024 | ||
| Bob Lapetina | PAO and VP Finance & Corporate | $71,198 | Mixed | 02 Jan 2024 | ||
| Kinney Horn | Chief Business Officer | $0 | -$2,300,855 | -100% | Mixed | 04 Aug 2026 |
| Phil Noland Roberts | Chief Technology Officer | Mixed | 13 Dec 2023 | |||
| Michael Widlitz | Director | Mixed | 28 May 2021 | |||
| Michael Lefenfeld | Director | Mixed | 08 Jun 2023 | |||
| Dennis H. Giesing | Chief Development Officer | Mixed | 08 Jun 2023 | |||
| Carol Schafer | Director | Mixed | 10 Jun 2026 | |||
| Corleen M. Roche | Chief Financial Officer | Mixed | 08 Jun 2023 |
Recent insider transactions for Immunome Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Isaac Barchas | IMNM | Common Stock | Sale | -10.7% | $301,058 | $27.25 | -11,048 | 92,211 | 12 Aug 2026 | Direct |
| Isaac Barchas | IMNM | Common Stock | Sale | -100% | $1,633,893 | $26.23 | -62,291 | 0 | 11 Aug 2026 | See footnote |
| Isaac Barchas | IMNM | Common Stock | Sale | -14% | $263,959 | $26.07 | -10,125 | 62,291 | 10 Aug 2026 | See footnote |
| Isaac Barchas | IMNM | Common Stock | Sale | -17.4% | $397,363 | $26.06 | -15,248 | 72,416 | 07 Aug 2026 | See footnote |
| Isaac Barchas | IMNM | Common Stock | Sale | -19.2% | $543,090 | $26.06 | -20,840 | 87,664 | 06 Aug 2026 | See footnote |
| Kinney Horn | IMNM | Common Stock | Sale | -100% | $2,273,555 | $25.09 | -90,616 | 0 | 04 Aug 2026 | Direct |
| Kinney Horn | IMNM | Common Stock | Options Exercise | 90,616 | 90,616 | 04 Aug 2026 | Direct | |||
| Kinney Horn | IMNM | Employee Stock Option (right to buy) | Options Exercise | -53.6% | -90,616 | 78,542 | 04 Aug 2026 | Direct | ||
| Kinney Horn | IMNM | Common Stock | Award | 31,250 | 31,250 | 23 Jul 2026 | Direct | |||
| Kinney Horn | IMNM | Employee Stock Option (right to buy) | Award | 62,500 | 62,500 | 23 Jul 2026 | Direct | |||
| Philip Tsai | IMNM | Common Stock | Award | 88.3% | 38,250 | 81,550 | 23 Jul 2026 | Direct | ||
| Philip Tsai | IMNM | Employee Stock Option (right to buy) | Award | 76,500 | 76,500 | 23 Jul 2026 | Direct | |||
| Sandra G. Stoneman | IMNM | Common Stock | Award | 688.6% | 38,250 | 43,805 | 23 Jul 2026 | Direct | ||
| Sandra G. Stoneman | IMNM | Employee Stock Option (right to buy) | Award | 76,500 | 76,500 | 23 Jul 2026 | Direct | |||
| Jack Higgins | IMNM | Common Stock | Award | 173.9% | 38,250 | 60,250 | 23 Jul 2026 | Direct | ||
| Jack Higgins | IMNM | Employee Stock Option (right to buy) | Award | 76,500 | 76,500 | 23 Jul 2026 | Direct | |||
| Max Rosett | IMNM | Common Stock | Award | 87.4% | 47,250 | 101,287 | 23 Jul 2026 | Direct | ||
| Max Rosett | IMNM | Employee Stock Option (right to buy) | Award | 94,500 | 94,500 | 23 Jul 2026 | Direct | |||
| Robert Lechleider | IMNM | Common Stock | Award | 341.7% | 54,000 | 69,805 | 23 Jul 2026 | Direct | ||
| Robert Lechleider | IMNM | Employee Stock Option (right to buy) | Award | 108,000 | 108,000 | 23 Jul 2026 | Direct | |||
| Clay B. Siegall | IMNM | Common Stock | Award | 26.1% | 180,000 | 870,704 | 23 Jul 2026 | Direct | ||
| Clay B. Siegall | IMNM | Employee Stock Option (right to buy) | Award | 360,000 | 360,000 | 23 Jul 2026 | Direct | |||
| Kinney Horn | IMNM | Common Stock | Sale | -100% | $27,300 | $25.00 | -1,092 | 0 | 07 Jul 2026 | Direct |
| Kinney Horn | IMNM | Common Stock | Options Exercise | 1,092 | 1,092 | 07 Jul 2026 | Direct | |||
| Kinney Horn | IMNM | Employee Stock Option (right to buy) | Options Exercise | -0.84% | -1,092 | 128,908 | 07 Jul 2026 | Direct | ||
| Isaac Barchas | IMNM | Common Stock | Sale | -13.5% | $409,125 | $24.20 | -16,906 | 108,504 | 07 Jul 2026 | See footnote |
| Isaac Barchas | IMNM | Common Stock | Sale | -39.8% | $2,003,396 | $24.11 | -83,094 | 125,410 | 06 Jul 2026 | See footnote |
| Robert Lechleider | IMNM | Common Stock | Sale | -77.7% | $1,244,331 | $22.62 | -55,000 | 15,805 | 02 Jul 2026 | Direct |
| Robert Lechleider | IMNM | Common Stock | Options Exercise | 348% | 55,000 | 70,805 | 02 Jul 2026 | Direct | ||
| Robert Lechleider | IMNM | Employee Stock Option (right to buy) | Options Exercise | -15.9% | -55,000 | 290,000 | 02 Jul 2026 | Direct | ||
| Isaac Barchas | IMNM | Common Stock | Sale | -32.4% | $2,258,848 | $22.59 | -100,000 | 208,504 | 02 Jul 2026 | See footnote |
| Isaac Barchas | IMNM | Common Stock | Sale | -24.7% | $2,134,176 | $21.12 | -101,050 | 308,504 | 30 Jun 2026 | See footnotes |
| Robert Lechleider | IMNM | Common Stock | Sale | -77.7% | $1,091,662 | $19.85 | -55,000 | 15,805 | 25 Jun 2026 | Direct |
| Robert Lechleider | IMNM | Common Stock | Options Exercise | 348% | 55,000 | 70,805 | 25 Jun 2026 | Direct | ||
| Robert Lechleider | IMNM | Employee Stock Option (right to buy) | Options Exercise | -13.8% | -55,000 | 345,000 | 25 Jun 2026 | Direct | ||
| Max Rosett | IMNM | Common Stock | Sale | -52.6% | $1,093,800 | $18.23 | -60,000 | 54,037 | 15 Jun 2026 | Direct |
| Max Rosett | IMNM | Common Stock | Options Exercise | 111% | 60,000 | 114,037 | 15 Jun 2026 | Direct | ||
| Max Rosett | IMNM | Stock Option (right to buy) | Options Exercise | -100% | -60,000 | 0 | 15 Jun 2026 | Direct | ||
| Sandra M. Swain | IMNM | Director Stock Option (right to buy)` | Award | 9,897 | 9,897 | 10 Jun 2026 | Direct | |||
| Philip Wagenheim | IMNM | Director Stock Option (right to buy) | Award | 9,897 | 9,897 | 10 Jun 2026 | Direct | |||
| Jean Jacques Bienaime | IMNM | Director Stock Option (right to buy) | Award | 9,897 | 9,897 | 10 Jun 2026 | Direct | |||
| James P. Boylan | IMNM | Director Stock Option (right to buy) | Award | 9,897 | 9,897 | 10 Jun 2026 | Direct | |||
| Isaac Barchas | IMNM | Director Stock Option (right to buy) | Award | 9,897 | 9,897 | 10 Jun 2026 | Direct | |||
| Carol Schafer | IMNM | Director Stock Option (right to buy) | Award | 9,897 | 9,897 | 10 Jun 2026 | Direct | |||
| Jean Jacques Bienaime | IMNM | Common Stock | Purchase | 31.9% | $204,260 | $19.45 | 10,500 | 43,415 | 05 Jun 2026 | Direct |
| Jean Jacques Bienaime | IMNM | Common Stock | Sale | -24.2% | $203,820 | $19.41 | -10,500 | 32,915 | 05 Jun 2026 | Direct |
| Jean Jacques Bienaime | IMNM | Common Stock | Purchase | 13% | $103,500 | $20.70 | 5,000 | 43,415 | 15 May 2026 | Direct |
| Jack Higgins | IMNM | Common Stock | Sale | -30% | $204,238 | $21.64 | -9,438 | 22,000 | 02 Apr 2026 | Direct |
| Max Rosett | IMNM | Common Stock | Sale | -54.6% | $1,424,916 | $21.92 | -65,000 | 54,037 | 02 Apr 2026 | Direct |
| Max Rosett | IMNM | Common Stock | Options Exercise | 150.7% | 71,561 | 119,037 | 02 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.